Browsing Tag
Eli Lilly and Company
145 posts
Rznomics gets FDA RMAT status for RZ-001, but can one liver cancer signal carry a platform story?
RNA editing has a regulatory opening in liver cancer. Rznomics now must prove RZ-001 can turn FDA momentum into durable clinical value.
Lilly bets up to $2.3bn on Ajax Therapeutics to crack the resistant myelofibrosis market with a Type II JAK2 inhibitor
Lilly is paying up to $2.3B for Ajax Therapeutics' Type II JAK2 inhibitor. The real question is whether it can crack Incyte's Jakafi grip on myelofibrosis.
Eli Lilly (NYSE: LLY) bets on oral GLP-1 Foundayo and retatrutide to reclaim its $1tn valuation
Eli Lilly (NYSE: LLY) launched Foundayo, the world's first oral GLP-1 for obesity, in April 2026 and reports Q1 earnings April 30. Full pipeline and risk analysis for retail investors.
Why a tiny cancer biotech suddenly looks worth more than $2bn to Eli Lilly
Eli Lilly is reportedly nearing a $2 billion-plus Kelonia deal. Read what it could mean for Lilly’s cancer pipeline, CAR-T economics, and LLY stock.
Walmart (NYSE: WMT) expands GLP-1 support as retail healthcare competition moves beyond the prescription counter
Walmart is expanding GLP-1 support with virtual care, nutrition, and pharmacy access. Read why this could deepen its healthcare moat.
Can a new IL-13 drug quietly challenge Dupixent’s dominance in eczema treatment?
Apogee Therapeutics’ APEX data could reshape eczema treatment competition. Discover what it means for Dupixent, Ebglyss, and investors.
From Eli Lilly to Hims & Hers: what Kathryn Beiser’s move says about the telehealth platform’s ambitions
Hims & Hers Health appoints Kathryn Beiser as Chief Communications Officer. Explore what the move signals about strategy, growth, and investor sentiment.
Why Eli Lilly’s Zepbound just tightened its grip on the obesity drug market in 2026
Find out how Eli Lilly and Company is strengthening Zepbound’s market dominance with a multi-dose KwikPen and reshaping obesity drug access in 2026.
Can Eli Lilly and Company’s Omvoh reset expectations for long-term Crohn’s disease control?
Three-year Omvoh data shows durable steroid-free remission in Crohn’s disease. Read how this reshapes Eli Lilly and Company’s long-term strategy.
Why Eli Lilly and Company is stockpiling a weight loss pill before the FDA has even said yes
Eli Lilly and Company is ramping inventory ahead of a key FDA decision on its oral weight loss pill. Find out what this signals for obesity drugs and investors.